Governor Glenn Youngkin Announces Sports Medicine Company to Expand in the City of Norfolk, Creating 92 New Jobs

RICHMOND, VA  (Office of Governor Glenn Youngkin) – Governor Glenn Youngkin today announced that Embody, Inc., a Norfolk-based medical device company developing novel collagen-based technologies for soft tissue repair, will invest $5 million to expand its headquarters at Innovation Research Park at Old Dominion University in the City of Norfolk. The company will add 10,000


2022’s Most & Least Innovative States

(WalletHub) – Innovation is a principal driver of U.S. economic growth. In 2022, the U.S. will spend nearly $600 billion on research and development — more than any other country in the world and more than 25% of the world’s total — helping the nation rank third on the Global Innovation Index. According to the results of


One of World’s Top Innovators Joins Focused Ultrasound Foundation as Chief Technology Officer

Charlottesville, Va., – Rick Hamilton, a leading inventor and authority on technology and innovation, has joined the Foundation as Managing Director and Chief Technology Officer. Hamilton is the one of the world’s most prolific inventors with more than 1,040 patents, standing just behind Thomas Edison. He has spent nearly 30 years at Fortune 50 organizations and


Carilion Clinic, Richmond firm part of $3.5M concussion grant

Clinical trial to follow 300 patients Roanoke, VA (Virginia Business) – Roanoke-based Carilion Clinic and Richmond’s BRAINBox Solutions Inc. are part of a $3.5 million National Institutes of Health grant to research and develop a new way to diagnose brain injuries in the elderly. The research will include enrolling 300 patients with head trauma and


It’s Time for NIH to Uphold the Law, Once Again

“As then NIH Director Elias Zerhouni noted in 2004 while rejecting the first march in petition seeking to impose price controls on a successfully commercialized product: ‘… the extraordinary remedy of march-in rights is not an appropriate means of controlling prices.’ That was correct then and remains so today.” /IPWatchdog /As discussed previously, the critics are in full howl


ZielBio Announces First Patient Dosed in Phase 1/2 Clinical Trial of ZB131, Its Novel Monoclonal Antibody Targeting Cancer Specific Plectin

First-in-human, open-label, dose escalation study will evaluate ZB131 in patients who have solid tumors with high CSP expression ZB131 clinical trial open and enrolling patients CHARLOTTESVILLE, Va./PRNewswire/ — ZielBio, Inc., a clinical stage biotechnology company discovering new treatments for cancer through its innovative ZielFind drug discovery platform, today announced the first patient dosed in its